PHILADELPHIA--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced at the American Society of Nephrology Renal Week 2008 in Philadelphia positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. In the Phase 2 study analysis presented by Iain Macdougall, M.D., Hematide clinical investigator and honorary senior lecturer at King’s College Hospital in London, 182 patients using Hematide once every four weeks (monthly) for up to 23 months successfully maintained average hemoglobin (Hb) levels within an 11 to 12 g/dL target range.
